Skip to main content

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience.

Publication ,  Journal Article
Anderson, JE; Litzow, MR; Appelbaum, FR; Schoch, G; Fisher, LD; Buckner, CD; Petersen, FB; Crawford, SW; Press, OW; Sanders, JE
Published in: J Clin Oncol
December 1993

PURPOSE: To analyze results of 127 patients undergoing myeloablative therapy followed by marrow transplantation for relapsed or refractory Hodgkin's disease. PATIENTS AND METHODS: Twenty-three patients had primary refractory disease, 34 were in early first relapse or second complete remission (CR), and 70 had refractory first relapse or disease beyond second CR. Preparative regimens included total-body irradiation (TBI) and chemotherapy (n = 61) or chemotherapy only (n = 66). Sixty-eight patients received autologous marrow, six syngeneic marrow, and 53 allogeneic marrow. RESULTS: The 5-year actuarial probabilities of survival, event-free survival (EFS), relapse, and nonrelapse mortality for the entire group were 21%, 18%, 65%, and 49%, respectively. HLA-identical allogeneic marrow recipients had a statistically lower relapse rate compared with recipients of autologous marrow, but survival, EFS, and nonrelapse mortality rates were not significantly different. In the multivariate analysis, higher performance status and absence of bulky disease predicted for improved EFS and lower relapse rates, while fewer prior treatment regimens predicted for improved EFS and lower nonrelapse mortality rates. Additionally, the univariate analysis showed that patients who underwent transplantation with disease refractory to chemotherapy or beyond second CR had a worse outcome compared with those who had less advanced disease. CONCLUSION: Outcome with transplantation for patients with Hodgkin's disease is improved if transplantation is performed early after relapse when disease burden is less, tumor chemosensitivity is greater, and the patient is likely to have a better performance status. The use of HLA-matched sibling marrow results in a lower relapse rate and, thus, for some individuals, may be preferable to the use of autologous marrow.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

December 1993

Volume

11

Issue

12

Start / End Page

2342 / 2350

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Transplantation, Isogeneic
  • Transplantation, Homologous
  • Transplantation, Autologous
  • Survival Analysis
  • Recurrence
  • Proportional Hazards Models
  • Oncology & Carcinogenesis
  • Multivariate Analysis
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Anderson, J. E., Litzow, M. R., Appelbaum, F. R., Schoch, G., Fisher, L. D., Buckner, C. D., … Sanders, J. E. (1993). Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol, 11(12), 2342–2350. https://doi.org/10.1200/JCO.1993.11.12.2342
Anderson, J. E., M. R. Litzow, F. R. Appelbaum, G. Schoch, L. D. Fisher, C. D. Buckner, F. B. Petersen, S. W. Crawford, O. W. Press, and J. E. Sanders. “Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience.J Clin Oncol 11, no. 12 (December 1993): 2342–50. https://doi.org/10.1200/JCO.1993.11.12.2342.
Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol. 1993 Dec;11(12):2342–50.
Anderson, J. E., et al. “Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience.J Clin Oncol, vol. 11, no. 12, Dec. 1993, pp. 2342–50. Pubmed, doi:10.1200/JCO.1993.11.12.2342.
Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD, Petersen FB, Crawford SW, Press OW, Sanders JE. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol. 1993 Dec;11(12):2342–2350.

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

December 1993

Volume

11

Issue

12

Start / End Page

2342 / 2350

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Transplantation, Isogeneic
  • Transplantation, Homologous
  • Transplantation, Autologous
  • Survival Analysis
  • Recurrence
  • Proportional Hazards Models
  • Oncology & Carcinogenesis
  • Multivariate Analysis
  • Middle Aged